FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019303762> ?p ?o ?g. }

• W2019303762 endingPage "1229" @default.
• W2019303762 startingPage "1221" @default.
• W2019303762 abstract "Clinical trials have reported a substantial variation in the risk of infection related to anti-EGFR monoclonal antibodies (mAbs) cetuximab and panitumumab. We performed a systematic review and meta-analysis to assess the infection risk in cancer patients treated with anti-EGFR mAbs.We searched PubMed and the ASCO online database of meeting abstracts up to January 2014 for relevant clinical trials. Eligible studies included randomized controlled trials (RCTs) of cetuximab and panitumumab that reported adequate safety data for grade 3-4 infection or febrile neutropenia (FN). The summary incidence, relative risk (RR) and 95% confidence intervals (CIs) were calculated.A total of 14,957 patients from 28 trials were included. Treatment with anti-EGFR mAbs was associated with an increased risk of high-grade infection (RR, 1.49; 95% CI, 1.33-1.66; P<0.001) and FN (RR, 1.27; 95% CI, 1.09-1.48; P=0.002). The incidence of high-grade infection and FN due to anti-EGFR mAbs was 9.3% (95% CI, 7.2-12.0%) and 5.3% (95% CI, 3.3-8.3%), respectively. A significantly increased risk of high-grade infection was observed in all subgroups analyses (type of anti-EGFR mAb, therapy of control arm and duration of treatment) except for tumor type (only colorectal cancer and non-small cell lung cancer (NSCLC) groups had the increased risk). Subgroup analyses revealed a significantly increased risk of FN in the following subgroups: cetuximab, NSCLC and treatment duration longer than the median of all trials (3.1months).The use of anti-EGFR mAbs is associated with a significantly higher risk of high-grade infection and febrile neutropenia." @default.
• W2019303762 created "2016-06-24" @default.
• W2019303762 creator A5018322323 @default.
• W2019303762 creator A5048971592 @default.
• W2019303762 creator A5080426443 @default.
• W2019303762 date "2014-12-01" @default.
• W2019303762 modified "2023-10-16" @default.
• W2019303762 title "Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: A systematic review and meta-analysis" @default.
• W2019303762 cites W1964321121 @default.
• W2019303762 cites W1964435302 @default.
• W2019303762 cites W1974024530 @default.
• W2019303762 cites W1979902684 @default.
• W2019303762 cites W1986833466 @default.
• W2019303762 cites W2002226820 @default.
• W2019303762 cites W2005501262 @default.
• W2019303762 cites W2014129405 @default.
• W2019303762 cites W2014908282 @default.
• W2019303762 cites W2017663593 @default.
• W2019303762 cites W204046373 @default.
• W2019303762 cites W2045363698 @default.
• W2019303762 cites W2049050498 @default.
• W2019303762 cites W2052348998 @default.
• W2019303762 cites W2054340543 @default.
• W2019303762 cites W2060887776 @default.
• W2019303762 cites W2076169486 @default.
• W2019303762 cites W2079286299 @default.
• W2019303762 cites W2086127297 @default.
• W2019303762 cites W2092246935 @default.
• W2019303762 cites W2093207065 @default.
• W2019303762 cites W2098354753 @default.
• W2019303762 cites W2101027485 @default.
• W2019303762 cites W2104580737 @default.
• W2019303762 cites W2107328434 @default.
• W2019303762 cites W2112660136 @default.
• W2019303762 cites W2112845420 @default.
• W2019303762 cites W2114610003 @default.
• W2019303762 cites W2116385092 @default.
• W2019303762 cites W2119209952 @default.
• W2019303762 cites W2121138562 @default.
• W2019303762 cites W2124621771 @default.
• W2019303762 cites W2125435699 @default.
• W2019303762 cites W2129255527 @default.
• W2019303762 cites W2132352600 @default.
• W2019303762 cites W2136781635 @default.
• W2019303762 cites W2143847499 @default.
• W2019303762 cites W2152362765 @default.
• W2019303762 cites W2155384808 @default.
• W2019303762 cites W2156700619 @default.
• W2019303762 cites W2157823046 @default.
• W2019303762 cites W2160367964 @default.
• W2019303762 cites W2166559675 @default.
• W2019303762 cites W2167123965 @default.
• W2019303762 cites W2168340462 @default.
• W2019303762 cites W2409420104 @default.
• W2019303762 cites W4385789423 @default.
• W2019303762 doi "https://doi.org/10.1016/j.ctrv.2014.09.002" @default.
• W2019303762 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25288497" @default.
• W2019303762 hasPublicationYear "2014" @default.
• W2019303762 type Work @default.
• W2019303762 sameAs 2019303762 @default.
• W2019303762 citedByCount "24" @default.
• W2019303762 countsByYear W20193037622015 @default.
• W2019303762 countsByYear W20193037622016 @default.
• W2019303762 countsByYear W20193037622017 @default.
• W2019303762 countsByYear W20193037622018 @default.
• W2019303762 countsByYear W20193037622021 @default.
• W2019303762 countsByYear W20193037622022 @default.
• W2019303762 countsByYear W20193037622023 @default.
• W2019303762 crossrefType "journal-article" @default.
• W2019303762 hasAuthorship W2019303762A5018322323 @default.
• W2019303762 hasAuthorship W2019303762A5048971592 @default.
• W2019303762 hasAuthorship W2019303762A5080426443 @default.
• W2019303762 hasConcept C120665830 @default.
• W2019303762 hasConcept C121332964 @default.
• W2019303762 hasConcept C121608353 @default.
• W2019303762 hasConcept C126322002 @default.
• W2019303762 hasConcept C143998085 @default.
• W2019303762 hasConcept C168563851 @default.
• W2019303762 hasConcept C2776256026 @default.
• W2019303762 hasConcept C2776694085 @default.
• W2019303762 hasConcept C2777063308 @default.
• W2019303762 hasConcept C2778332735 @default.
• W2019303762 hasConcept C2779998722 @default.
• W2019303762 hasConcept C44249647 @default.
• W2019303762 hasConcept C526805850 @default.
• W2019303762 hasConcept C535046627 @default.
• W2019303762 hasConcept C61511704 @default.
• W2019303762 hasConcept C71924100 @default.
• W2019303762 hasConcept C82789193 @default.
• W2019303762 hasConcept C95190672 @default.
• W2019303762 hasConceptScore W2019303762C120665830 @default.
• W2019303762 hasConceptScore W2019303762C121332964 @default.
• W2019303762 hasConceptScore W2019303762C121608353 @default.
• W2019303762 hasConceptScore W2019303762C126322002 @default.
• W2019303762 hasConceptScore W2019303762C143998085 @default.
• W2019303762 hasConceptScore W2019303762C168563851 @default.
• W2019303762 hasConceptScore W2019303762C2776256026 @default.
• W2019303762 hasConceptScore W2019303762C2776694085 @default.

• next